These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20473060)

  • 1. Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.
    Warden D; Trivedi MH; Wisniewski SR; Kurian B; Zisook S; Kornstein SG; Friedman ES; Miyahara S; Leuchter AF; Fava M; Rush AJ
    J Clin Psychopharmacol; 2010 Jun; 30(3):259-66. PubMed ID: 20473060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study.
    Daly EJ; Trivedi MH; Fava M; Shelton R; Wisniewski SR; Morris DW; Stegman D; Preskorn SH; Rush AJ
    J Clin Psychopharmacol; 2011 Feb; 31(1):31-8. PubMed ID: 21192140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients.
    Kostev K; Rex J; Eith T; Heilmaier C
    Ger Med Sci; 2014; 12():Doc15. PubMed ID: 25332703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between suicidality and treatment with selective serotonin reuptake inhibitors in older people with major depression: a systematic review.
    KoKoAung E; Cavenett S; McArthur A; Aromataris E
    JBI Database System Rev Implement Rep; 2015 Apr; 13(3):174-205. PubMed ID: 26447056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital patients' perceptions during treatment and early discontinuation of serotonin selective reuptake inhibitor antidepressants.
    Woolley SB; Fredman L; Goethe JW; Lincoln AK; Heeren T
    J Clin Psychopharmacol; 2010 Dec; 30(6):716-9. PubMed ID: 21105288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.
    Perlis RH; Purcell S; Fava M; Fagerness J; Rush AJ; Trivedi MH; Smoller JW
    Arch Gen Psychiatry; 2007 Jun; 64(6):689-97. PubMed ID: 17548750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying risk for attrition during treatment for depression.
    Warden D; Trivedi MH; Wisniewski SR; Lesser IM; Mitchell J; Balasubramani GK; Fava M; Shores-Wilson K; Stegman D; Rush AJ
    Psychother Psychosom; 2009; 78(6):372-9. PubMed ID: 19738403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    Fava M; Thase ME; DeBattista C
    J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
    J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial.
    Rucci P; Frank E; Scocco P; Calugi S; Miniati M; Fagiolini A; Cassano GB
    Depress Anxiety; 2011 Apr; 28(4):303-9. PubMed ID: 21308882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
    Dunlop BW; Crits-Christoph P; Evans DL; Hirschowitz J; Solvason HB; Rickels K; Garlow SJ; Gallop RJ; Ninan PT
    J Clin Psychopharmacol; 2007 Dec; 27(6):614-9. PubMed ID: 18004129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.
    Zisook S; Trivedi MH; Warden D; Lebowitz B; Thase ME; Stewart JW; Moutier C; Fava M; Wisniewski SR; Luther J; Rush AJ
    J Affect Disord; 2009 Sep; 117(1-2):63-73. PubMed ID: 19217668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Escitalopram for treatment of major depressive disorder in adults].
    Llorca PM; Brousse G; Schwan R
    Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.